	US 11,865,103 B2
	Methods of treating disorders associated with glycosylation defective proteins
Alagramam N. Kumar, Cleveland, OH (US); and Suhasini Gopal Ramanujam, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Filed on Sep. 7, 2021, as Appl. No. 17/468,274.
Application 17/468,274 is a continuation of application No. 16/793,861, filed on Feb. 18, 2020, granted, now 11,110,076.
Application 16/793,861 is a continuation in part of application No. 16/340,352, granted, now 10,561,636, issued on Feb. 18, 2020, previously published as PCT/US2017/055914, filed on Oct. 10, 2017.
Claims priority of provisional application 62/405,351, filed on Oct. 7, 2016.
Prior Publication US 2022/0168269 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/12 (2006.01); A61K 31/34 (2006.01); A61K 31/335 (2006.01); A61K 31/435 (2006.01); A61K 33/00 (2006.01); A61K 31/357 (2006.01); A61P 27/16 (2006.01); A61K 31/343 (2006.01)

CPC A61K 31/357 (2013.01) [A61K 31/343 (2013.01); A61P 27/16 (2018.01)]

8 Claims

1. A method of liberating deleterious glycosylation-defective misfolded proteins that accumulate in endoplasmic reticulum (ER) of a subject's cells that are associated with and/or causative of a disease or disorder in a subject in need thereof, the method comprising:

administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor, wherein the SERCA inhibitor induces unconventional secretory pathway transport of aggregated glycosylation-defective protein from endoplasmic reticulum of cells of the subject.